FIVE PRIME THERAPEUTICS INC Business Operations Contracts & Agreements
24 Contracts & Agreements
- Collaboration Agreements (21 contracts)
- Indemnification Agreements (1)
- Sales Agreements (1)
- Services Agreements (1)
- Sales Agreement by and between the Company and Cowen and Company, LLC, dated as of August 6, 2020 (Filed With SEC on August 6, 2020)
- Amendment No. 1 to the License and Collaboration Agreement by and between the company and Zai Lab (Shanghai) Co., Ltd., dated as of December 21, 2018 (Filed With SEC on February 26, 2019)
- License and Collaboration Agreement, dated as of December 19, 2017, by and between the company and Zai Lab (Shanghai) Co., Ltd (Filed With SEC on February 27, 2018)
- Amendment No. 1 to the Research Collaboration and License Agreement (Filed With SEC on March 11, 2016)
- Amendment No. 3 to the Respiratory Diseases Research Collaboration and License Agreement (Filed With SEC on March 11, 2016)
- Amendment No. 2 to the Research Collaboration and License Agreement (Filed With SEC on March 11, 2016)
- Research Collaboration and License Agreement (Filed With SEC on November 5, 2015)
- CLINICAL TRIAL COLLABORATION AGREEMENT (Filed With SEC on March 18, 2015)
- Amendment No. 1 to the Research Collaboration and License Agreement (Filed With SEC on August 7, 2014)
- Amendment No. 2 to the Respiratory Diseases Research Collaboration and License Agreement (Filed With SEC on August 7, 2014)
- Research Collaboration and License Agreement (Filed With SEC on May 12, 2014)
- AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases ResearchProgram Expansion) (Filed With SEC on August 16, 2013)
- RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc. (Filed With SEC on August 16, 2013)
- License andCollaboration Agreement by and between Five Prime Therapeutics, Inc. and Human Genome Sciences, Inc. LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 16, 2013)
- Research Collaboration and License Agreement (Filed With SEC on August 16, 2013)
- INDEMNIFICATION AGREEMENT (Filed With SEC on August 16, 2013)
- Master Services Agreement (Filed With SEC on July 26, 2013)
- AMENDMENT No. 1 to the RESEARCH COLLABORATION AND LICENSE AGREEMENT (Muscle Diseases ResearchProgram Expansion) (Filed With SEC on July 26, 2013)
- Amendment No. 1 to the Respiratory Diseases Research Collaboration and License Agreement (Filed With SEC on July 26, 2013)
- RESPIRATORY DISEASES RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between Glaxo Group Limited and Five Prime Therapeutics, Inc. (Filed With SEC on July 26, 2013)
- License andCollaboration Agreement by and between Five Prime Therapeutics, Inc. and Human Genome Sciences, Inc. LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on July 26, 2013)
- Research Collaboration and License Agreement (Filed With SEC on July 26, 2013)
- RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc. RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on August 16, 2013)
- RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between GlaxoSmithKline LLC and Five Prime Therapeutics, Inc. RESEARCH COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on July 26, 2013)
